# Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes

> **NCT00097084** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 324 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin detemir
- **DRUG:** insulin glargine
- **DRUG:** insulin aspart

## Key facts

- **NCT ID:** NCT00097084
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 324 (ACTUAL)
- **Last updated:** 2017-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00097084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00097084, "Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT00097084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*